Skip to main content
Erschienen in: Cellular Oncology 5/2012

01.10.2012 | Original Paper

Skewed immunological balance between Th17 (CD4+IL17A+) and Treg (CD4+CD25+FOXP3+) cells in human oral squamous cell carcinoma

verfasst von: Poonam Gaur, Gulam Abdul Qadir, Shilpy Upadhyay, Avadhesh Kumar Singh, Nootan Kumar Shukla, Satya Narayan Das

Erschienen in: Cellular Oncology | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Several studies have documented modulation of Th17 and T regulatory (Treg) cells in various human malignancies which may vary with the type and extent of the disease. However, such data in patients with oral cancer is scarce and hence the current study was designed to elaborate the immunological balance between these two T cell subsets in oral cancer.

Methods and results

We analyzed various T cell subsets in the peripheral blood of 45 oral squamous cell carcinoma (OSCC) patients and 40 healthy volunteers. We found that, compared with the healthy controls, patients had a significantly (p < 0.0001) higher proportion of both Th17 (CD4+IL17A+) and Treg (CD4+CD25+FOXP3+) cells, which further showed a reciprocal balance in relation to clinico-pathological parameters in patients. We also detected a circulating CD8+ subset of these cells in both patients and healthy controls, although the difference between the two groups was statistically insignificant. Higher frequencies of Th17 cells were found in patients with early stages and without lymph node involvement, while an increased prevalence of Tregs was associated with higher clinical stages and lymph node involvement. Moreover, Th17 cells were quantitatively and positively correlated to CD4+T and CD8+T cells and inversely correlated with Tregs. Contrarily, Tregs showed a negative association with CD4+T and CD8+T cells.

Conclusions

Our results suggest an increase in Th17/Tregs ratio in early stages and a decrease in this ratio in higher stages of oral cancer. Such counter regulation of Th17 and Tregs may be a significant prognostic factor in oral cancer patients.
Literatur
1.
Zurück zum Zitat J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, D.M. Parkin, GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 (Lyon, France: International Agency for Research on Cancer, 2010). Available from: http://globocan.iarc.fr. Accessed on 15 March 2012 J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, D.M. Parkin, GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 (Lyon, France: International Agency for Research on Cancer, 2010). Available from: http://​globocan.​iarc.​fr. Accessed on 15 March 2012
2.
Zurück zum Zitat M.C. Chang, C.P. Chiang, C.L. Lin, J.J. Lee, L.J. Hahn, J.H. Jeng, Cell-mediated immunity and head and neck cancer: with special emphasis on betel quid chewing habit. Oral Oncol. 41, 757–775 (2005)PubMedCrossRef M.C. Chang, C.P. Chiang, C.L. Lin, J.J. Lee, L.J. Hahn, J.H. Jeng, Cell-mediated immunity and head and neck cancer: with special emphasis on betel quid chewing habit. Oral Oncol. 41, 757–775 (2005)PubMedCrossRef
3.
Zurück zum Zitat S.N. Das, N.N. Khanna, S. Khanna, In vivo and in vitro observation of cellular immune parameters in squamous cell carcinoma of the oral cavity and its correlation with tumor load and prognosis. Cancer Invest. 4, 207–216 (1986)PubMedCrossRef S.N. Das, N.N. Khanna, S. Khanna, In vivo and in vitro observation of cellular immune parameters in squamous cell carcinoma of the oral cavity and its correlation with tumor load and prognosis. Cancer Invest. 4, 207–216 (1986)PubMedCrossRef
4.
Zurück zum Zitat T.P. Wustrow, C.G. Mahnke, Causes of immunosuppression in squamous cell carcinoma of the head and neck. Anticancer Res. 16, 2433–2468 (1996)PubMed T.P. Wustrow, C.G. Mahnke, Causes of immunosuppression in squamous cell carcinoma of the head and neck. Anticancer Res. 16, 2433–2468 (1996)PubMed
5.
Zurück zum Zitat E.Y. Woo, H. Yeh, C.S. Chu, K. Schlienger, R.G. Carroll, J.L. Riley, L.R. Kaiser, C.H. June, Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168, 4272–4276 (2002)PubMed E.Y. Woo, H. Yeh, C.S. Chu, K. Schlienger, R.G. Carroll, J.L. Riley, L.R. Kaiser, C.H. June, Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168, 4272–4276 (2002)PubMed
6.
Zurück zum Zitat U.K. Liyanage, T.T. Moore, H.G. Joo, Y. Tanaka, V. Herrmann, G. Doherty, J.A. Drebin, S.M. Strasberg, T.J. Eberlein, P.S. Goedegebuure, D.C. Linehan, Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169, 2756–2761 (2002)PubMed U.K. Liyanage, T.T. Moore, H.G. Joo, Y. Tanaka, V. Herrmann, G. Doherty, J.A. Drebin, S.M. Strasberg, T.J. Eberlein, P.S. Goedegebuure, D.C. Linehan, Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169, 2756–2761 (2002)PubMed
7.
Zurück zum Zitat A.M. Miller, K. Lundberg, V. Ozenci, A.H. Banham, M. Hellström, L. Egevad, P. Pisa, CD4 + CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J. Immunol. 177, 7398–7405 (2006)PubMed A.M. Miller, K. Lundberg, V. Ozenci, A.H. Banham, M. Hellström, L. Egevad, P. Pisa, CD4 + CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J. Immunol. 177, 7398–7405 (2006)PubMed
8.
Zurück zum Zitat L.A. Ormandy, T. Hillemann, H. Wedemeyer, M.P. Manns, T.F. Greten, F. Korangy, Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 65, 2457–2464 (2005)PubMedCrossRef L.A. Ormandy, T. Hillemann, H. Wedemeyer, M.P. Manns, T.F. Greten, F. Korangy, Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 65, 2457–2464 (2005)PubMedCrossRef
9.
Zurück zum Zitat T.J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J.R. Conejo-Garcia, L. Zhang, M. Burow, Y. Zhu, S. Wei, I. Kryczek, B. Daniel, A. Gordon, L. Myers, A. Lackner, M.L. Disis, K.L. Knutson, L. Chen, W. Zou, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942–949 (2004)PubMedCrossRef T.J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J.R. Conejo-Garcia, L. Zhang, M. Burow, Y. Zhu, S. Wei, I. Kryczek, B. Daniel, A. Gordon, L. Myers, A. Lackner, M.L. Disis, K.L. Knutson, L. Chen, W. Zou, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942–949 (2004)PubMedCrossRef
10.
Zurück zum Zitat A. Bamias, V. Koutsoukou, E. Terpos, M.L. Tsiatas, C. Liakos, O. Tsitsilonis, A. Rodolakis, Z. Voulgaris, G. Vlahos, T. Papageorgiou, G. Papatheodoridis, A. Archimandritis, A. Antsaklis, M.A. Dimopoulos, Correlation of NK T-like CD3 + CD56+ cells and CD4 + CD25 + (hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecol. Oncol. 108, 421–427 (2008)PubMedCrossRef A. Bamias, V. Koutsoukou, E. Terpos, M.L. Tsiatas, C. Liakos, O. Tsitsilonis, A. Rodolakis, Z. Voulgaris, G. Vlahos, T. Papageorgiou, G. Papatheodoridis, A. Archimandritis, A. Antsaklis, M.A. Dimopoulos, Correlation of NK T-like CD3 + CD56+ cells and CD4 + CD25 + (hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecol. Oncol. 108, 421–427 (2008)PubMedCrossRef
11.
Zurück zum Zitat J. Shimizu, S. Yamazaki, S. Sakaguchi, Induction of tumor immunity by removing CD25 + CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163, 5211–5218 (1999)PubMed J. Shimizu, S. Yamazaki, S. Sakaguchi, Induction of tumor immunity by removing CD25 + CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163, 5211–5218 (1999)PubMed
12.
Zurück zum Zitat I. Kryczek, M. Banerjee, P. Cheng, L. Vatan, W. Szeliga, S. Wei, E. Huang, E. Finlayson, D. Simeone, T.H. Welling, A. Chang, G. Coukos, R. Liu, W. Zou, Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114, 1141–1149 (2009)PubMedCrossRef I. Kryczek, M. Banerjee, P. Cheng, L. Vatan, W. Szeliga, S. Wei, E. Huang, E. Finlayson, D. Simeone, T.H. Welling, A. Chang, G. Coukos, R. Liu, W. Zou, Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114, 1141–1149 (2009)PubMedCrossRef
13.
Zurück zum Zitat X. Su, J. Ye, E.C. Hsueh, Y. Zhang, D.F. Hoft, G. Peng, Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J. Immunol. 184, 1630–1641 (2010)PubMedCrossRef X. Su, J. Ye, E.C. Hsueh, Y. Zhang, D.F. Hoft, G. Peng, Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J. Immunol. 184, 1630–1641 (2010)PubMedCrossRef
14.
Zurück zum Zitat J.P. Zhang, J. Yan, J. Xu, X.H. Pang, M.S. Chen, L. Li, C. Wu, S.P. Li, L. Zheng, Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J. Hepatol. 50, 980–989 (2009)PubMedCrossRef J.P. Zhang, J. Yan, J. Xu, X.H. Pang, M.S. Chen, L. Li, C. Wu, S.P. Li, L. Zheng, Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J. Hepatol. 50, 980–989 (2009)PubMedCrossRef
15.
Zurück zum Zitat K.S. Sfanos, T.C. Bruno, C.H. Maris, L. Xu, C.J. Thoburn, A.M. DeMarzo, A.K. Meeker, W.B. Isaacs, C.G. Drake, Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin. Cancer Res. 14, 3254–3261 (2008)PubMedCrossRef K.S. Sfanos, T.C. Bruno, C.H. Maris, L. Xu, C.J. Thoburn, A.M. DeMarzo, A.K. Meeker, W.B. Isaacs, C.G. Drake, Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin. Cancer Res. 14, 3254–3261 (2008)PubMedCrossRef
16.
Zurück zum Zitat K. Koyama, H. Kagamu, S. Miura, T. Hiura, T. Miyabayashi, R. Itoh, H. Kuriyama, H. Tanaka, J. Tanaka, H. Yoshizawa, K. Nakata, F. Gejyo, Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. Clin. Cancer Res. 14, 6770–6779 (2008)PubMedCrossRef K. Koyama, H. Kagamu, S. Miura, T. Hiura, T. Miyabayashi, R. Itoh, H. Kuriyama, H. Tanaka, J. Tanaka, H. Yoshizawa, K. Nakata, F. Gejyo, Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. Clin. Cancer Res. 14, 6770–6779 (2008)PubMedCrossRef
17.
Zurück zum Zitat Z.Z. Yang, A.J. Novak, S.C. Ziesmer, T.E. Witzig, S.M. Ansell, Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin’s lymphoma. Cancer Res. 69, 5522–5530 (2009)PubMedCrossRef Z.Z. Yang, A.J. Novak, S.C. Ziesmer, T.E. Witzig, S.M. Ansell, Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin’s lymphoma. Cancer Res. 69, 5522–5530 (2009)PubMedCrossRef
18.
Zurück zum Zitat C. Horlock, B. Stott, P.J. Dyson, M. Morishita, R.C. Coombes, P. Savage, J. Stebbing, The effects of transtuzumab on the CD4 + CD25 + FOXP3+ and CD4 + IL17A + T-cell axis in patients with breast cancer. Br. J. Cancer 100, 1061–1067 (2009)PubMedCrossRef C. Horlock, B. Stott, P.J. Dyson, M. Morishita, R.C. Coombes, P. Savage, J. Stebbing, The effects of transtuzumab on the CD4 + CD25 + FOXP3+ and CD4 + IL17A + T-cell axis in patients with breast cancer. Br. J. Cancer 100, 1061–1067 (2009)PubMedCrossRef
19.
Zurück zum Zitat I. Kryczek, S. Wei, L. Zou, S. Altuwaijri, W. Szeliga, J. Kolls, A. Chang, W. Zou, Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol. 178, 6730–6733 (2007)PubMed I. Kryczek, S. Wei, L. Zou, S. Altuwaijri, W. Szeliga, J. Kolls, A. Chang, W. Zou, Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol. 178, 6730–6733 (2007)PubMed
20.
Zurück zum Zitat E.S. Hwang, Transcriptional regulation of T helper 17 cell differentiation. Yonsei Med. J. 51, 484–491 (2010)PubMedCrossRef E.S. Hwang, Transcriptional regulation of T helper 17 cell differentiation. Yonsei Med. J. 51, 484–491 (2010)PubMedCrossRef
21.
Zurück zum Zitat J. Lohr, B. Knoechel, D. Caretto, A.K. Abbas, Balance of Th1 and Th17 effector and peripheral regulatory T cells. Microbes Infect. 11, 589–593 (2009)PubMedCrossRef J. Lohr, B. Knoechel, D. Caretto, A.K. Abbas, Balance of Th1 and Th17 effector and peripheral regulatory T cells. Microbes Infect. 11, 589–593 (2009)PubMedCrossRef
22.
Zurück zum Zitat E. Bettelli, M. Oukka, V.K. Kuchroo, T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8, 345–350 (2007)PubMedCrossRef E. Bettelli, M. Oukka, V.K. Kuchroo, T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8, 345–350 (2007)PubMedCrossRef
23.
Zurück zum Zitat A. O’Garra, P. Vieira, Regulatory T cells and mechanisms of immune system control. Nat. Med. 10, 801–805 (2004)PubMedCrossRef A. O’Garra, P. Vieira, Regulatory T cells and mechanisms of immune system control. Nat. Med. 10, 801–805 (2004)PubMedCrossRef
24.
Zurück zum Zitat C. Dong, TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. Immunol. 8, 337–348 (2008)PubMedCrossRef C. Dong, TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. Immunol. 8, 337–348 (2008)PubMedCrossRef
25.
Zurück zum Zitat A. Agarwal, M. Rani, G.K. Saha, T.M. Valarmathi, S. Bahadur, B.K. Mohanti, S.N. Das, Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma. Immunol. Invest. 32, 17–30 (2003)PubMedCrossRef A. Agarwal, M. Rani, G.K. Saha, T.M. Valarmathi, S. Bahadur, B.K. Mohanti, S.N. Das, Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma. Immunol. Invest. 32, 17–30 (2003)PubMedCrossRef
26.
Zurück zum Zitat C.S. Hinrichs, A. Kaiser, C.M. Paulos, L. Cassard, L. Sanchez-Perez, B. Heemskerk, C. Wrzesinski, Z.A. Borman, P. Muranski, N.P. Restifo, Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 114, 596–599 (2009)PubMedCrossRef C.S. Hinrichs, A. Kaiser, C.M. Paulos, L. Cassard, L. Sanchez-Perez, B. Heemskerk, C. Wrzesinski, Z.A. Borman, P. Muranski, N.P. Restifo, Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 114, 596–599 (2009)PubMedCrossRef
27.
Zurück zum Zitat Y. Miyahara, K. Odunsi, W. Chen, G. Peng, J. Matsuzaki, R.F. Wang, Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad of Sci USA 105, 15505–15510 (2008)CrossRef Y. Miyahara, K. Odunsi, W. Chen, G. Peng, J. Matsuzaki, R.F. Wang, Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad of Sci USA 105, 15505–15510 (2008)CrossRef
28.
Zurück zum Zitat J.J. Lee, Y.L. Chang, W.L. Lai, J.Y. Ko, M.Y. Kuo, C.P. Chiang, M. Azuma, C.W. Chen, J.S. Chia, Increased prevalence of interleukin-17-producing CD4(+) tumor infiltrating lymphocytes in human oral squamous cell carcinoma. Head Neck 33, 1301–1308 (2011)PubMedCrossRef J.J. Lee, Y.L. Chang, W.L. Lai, J.Y. Ko, M.Y. Kuo, C.P. Chiang, M. Azuma, C.W. Chen, J.S. Chia, Increased prevalence of interleukin-17-producing CD4(+) tumor infiltrating lymphocytes in human oral squamous cell carcinoma. Head Neck 33, 1301–1308 (2011)PubMedCrossRef
29.
Zurück zum Zitat P. Muranski, A. Boni, P.A. Antony, L. Cassard, K.R. Irvine, A. Kaiser, C.M. Paulos, D.C. Palmer, C.E. Touloukian, K. Ptak, L. Gattinoni, C. Wrzesinski, C.S. Hinrichs, K.W. Kerstann, L. Feigenbaum, C.C. Chan, N.P. Restifo, Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112, 362–373 (2008)PubMedCrossRef P. Muranski, A. Boni, P.A. Antony, L. Cassard, K.R. Irvine, A. Kaiser, C.M. Paulos, D.C. Palmer, C.E. Touloukian, K. Ptak, L. Gattinoni, C. Wrzesinski, C.S. Hinrichs, K.W. Kerstann, L. Feigenbaum, C.C. Chan, N.P. Restifo, Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112, 362–373 (2008)PubMedCrossRef
30.
Zurück zum Zitat N. Martin-Orozco, P. Muranski, Y. Chung, X.O. Yang, T. Yamazaki, S. Lu, P. Hwu, N.P. Restifo, W.W. Overwijk, C. Dong, T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31, 787–798 (2009)PubMedCrossRef N. Martin-Orozco, P. Muranski, Y. Chung, X.O. Yang, T. Yamazaki, S. Lu, P. Hwu, N.P. Restifo, W.W. Overwijk, C. Dong, T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31, 787–798 (2009)PubMedCrossRef
31.
Zurück zum Zitat M. Numasaki, J. Fukushi, M. Ono, S.K. Narula, P.J. Zavodny, T. Kudo, P.D. Robbins, H. Tahara, M.T. Lotze, Interleukin-17 promotes angiogenesis and tumor growth. Blood 101, 2620–2627 (2003)PubMedCrossRef M. Numasaki, J. Fukushi, M. Ono, S.K. Narula, P.J. Zavodny, T. Kudo, P.D. Robbins, H. Tahara, M.T. Lotze, Interleukin-17 promotes angiogenesis and tumor growth. Blood 101, 2620–2627 (2003)PubMedCrossRef
32.
Zurück zum Zitat M. Pelletier, L. Maggi, A. Micheletti, E. Lazzeri, N. Tamassia, C. Costantini, L. Cosmi, C. Lunardi, F. Annunziato, S. Romagnani, M.A. Cassatella, Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 115, 335–343 (2010)PubMedCrossRef M. Pelletier, L. Maggi, A. Micheletti, E. Lazzeri, N. Tamassia, C. Costantini, L. Cosmi, C. Lunardi, F. Annunziato, S. Romagnani, M.A. Cassatella, Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 115, 335–343 (2010)PubMedCrossRef
33.
Zurück zum Zitat L. Wang, T. Yi, M. Kortylewski, D.M. Pardoll, D. Zeng, H. Yu, IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway. J. Exp. Med. 206, 1457–1464 (2009)PubMedCrossRef L. Wang, T. Yi, M. Kortylewski, D.M. Pardoll, D. Zeng, H. Yu, IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway. J. Exp. Med. 206, 1457–1464 (2009)PubMedCrossRef
34.
Zurück zum Zitat W. Zou, N.P. Restifo, T(H)17 cells in tumour immunity and immunotherapy. Nat. Rev. Immunol. 10, 248–256 (2010)PubMedCrossRef W. Zou, N.P. Restifo, T(H)17 cells in tumour immunity and immunotherapy. Nat. Rev. Immunol. 10, 248–256 (2010)PubMedCrossRef
35.
Zurück zum Zitat X.O. Yang, R. Nurieva, G.J. Martinez, H.S. Kang, Y. Chung, B.P. Pappu, B. Shah, S.H. Chang, K.S. Schluns, S.S. Watowich, X.H. Feng, A.M. Jetten, C. Dong, Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 29, 44–56 (2008)PubMedCrossRef X.O. Yang, R. Nurieva, G.J. Martinez, H.S. Kang, Y. Chung, B.P. Pappu, B. Shah, S.H. Chang, K.S. Schluns, S.S. Watowich, X.H. Feng, A.M. Jetten, C. Dong, Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 29, 44–56 (2008)PubMedCrossRef
36.
Zurück zum Zitat K.M. Elias, A. Laurence, T.S. Davidson, G. Stephens, Y. Kanno, E.M. Shevach, J.J. O'Shea, Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood 111, 1013–1020 (2008)PubMedCrossRef K.M. Elias, A. Laurence, T.S. Davidson, G. Stephens, Y. Kanno, E.M. Shevach, J.J. O'Shea, Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood 111, 1013–1020 (2008)PubMedCrossRef
Metadaten
Titel
Skewed immunological balance between Th17 (CD4+IL17A+) and Treg (CD4+CD25+FOXP3+) cells in human oral squamous cell carcinoma
verfasst von
Poonam Gaur
Gulam Abdul Qadir
Shilpy Upadhyay
Avadhesh Kumar Singh
Nootan Kumar Shukla
Satya Narayan Das
Publikationsdatum
01.10.2012
Verlag
Springer Netherlands
Erschienen in
Cellular Oncology / Ausgabe 5/2012
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-012-0093-5

Weitere Artikel der Ausgabe 5/2012

Cellular Oncology 5/2012 Zur Ausgabe

Neu im Fachgebiet Pathologie